real-world safety analysis of deferiprone in patients with mds
Published 1 year ago • 324 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
2:10
drd versus vrd in patients with mm: a real-world retrospective analysis
-
4:09
real-world safety and efficacy of liso-cel in r/r large b-cell lymphoma
-
2:10
updated overall survival data on eltanexor for hma-refractory mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:14
real-world treatment patterns of patients with low-risk mds reinitiating esas
-
![why design history file (dhf) is important? [alexandros savvidis]](https://i.ytimg.com/vi/X9GediGNWk4/mqdefault.jpg)
35:59
why design history file (dhf) is important? [alexandros savvidis]
-
3:16
end stage multiple myeloma
-
7:54
patient/caregiver stories - living with mds
-
1:16
state of the art: mds
-
1:30
the prognostic value of patient-reported outcomes in mds
-
1:06
the prognostic value of self-reported fatigue on overall survival in patients with mds
-
1:34
perspectives on the management of low and high-risk mds
-
1:59
real-world outcomes of ide-cel in heavily pre-treated r/r mm
-
1:04
predictors of esa failure in patients with lr-mds with severe anemia
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
2:44
the impact of mutation screening on transplant decisions in mds
-
7:09
the role of real-world evidence in the evaluation of new drugs
-
2:27
milestone trial results: mrd response-adapted deferral of autosct in newly diagnosed myeloma
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
3:08
the treatment protocol for higher risk mds
-
1:47
real-world safety and efficacy of talquetamab for the treatment of r/r myeloma
-
2:07
emerging targeted treatments for mds